Endocrine comorbidities in patients with PsA treated with DMARD compared with patients with PsA not treated with DMARD*. Values are n (%) unless otherwise specified.
| Comorbidities | PsA Not Treated with DMARD, n = 665 | PsA Treated with DMARD, n = 2496 | OR | 95% CI |
|---|---|---|---|---|
| Diabetes mellitus | 194 (29.2) | 687 (27.5) | 0.9 | 0.8–1.1 |
| Hypothyroidism | 80 (12.0) | 32 (12.9) | 1.1 | 0.8–1.4 |
| Hyperthyroidism | 6 (0.9) | 40 (1.6) | 1.8 | 0.8–4.2 |
| Hyperparathyroidism | 4 (0.6) | 20 (0.8) | 1.3 | 0.5–3.9 |
| Hyperprolactinemia | 0 (0) | 2 (0.1) | 1.0 | 1.0–1.0 |
| Cushing disease | 1 (0.2) | 8 (0.3) | 2.1 | 0.3–17.1 |
| Diabetes insipidus | 1 (0.2) | 2 (0.1) | 0.5 | 0.1–5.9 |
| Addison disease | 0 (0) | 4 (0.2) | 1.0 | 1.0–1.0 |
| Osteoporosis | 70 (10.5) | 346 (13.9) | 1.4 | 1.0–1.8 |
↵* Nonbiological DMARD: hydroxychloroquine, sulfasalazine, methotrexate, azathioprine, leflunomide, and cyclosporine; and biological DMARD: adalimumab, etanercept, infliximab, and golimumab. PsA: psoriatic arthritis; DMARD: disease-modifying antirheumatic drug.